5 TIPS ABOUT BREAST CANCER RESEARCH YOU CAN USE TODAY

Genomic sequencing analysis of 733 HER2-amplified Main and metastatic breast tumours exposed considerable enrichment of mutations that activate RAS–MAPK signalling in advanced tumours treated with prior anti-HER2 therapies121. These mutations, which include NF1 and HER2 activating mutations, contribute to resistance to tucatinib and neratinib.Whi